Increased YKL-40 expression in patients with carotid atherosclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

  • Axel Gottlieb Michelsen
  • C.N. Rathcke
  • M. Skjelland
  • S. Holm
  • T. Ranheim
  • K. Krohg-Sorensen
  • M.F. Klingvall
  • F. Brosstad
  • E. Oie
  • drb459, drb459
  • P. Aukrust
  • Esben Bistrup Halvorsen
Objective: We hypothesized a role for the inflammatory protein YKL-40 in atherogenesis and plaque destabilization based on its role in macrophage activation, tissue remodeling, and angiogenesis. Methods: Serum YKL-40 levels were measured by enzyme immunoassay in 89 patients with carotid atherosclerosis and 20 healthy controls. Carotid expression of YKL-40 was examined by real time RT-PCR in 57 of the patients. Regulation and effect of YKL-40 were examined in THP-1 monocytes. Results: Our main findings were: (1) serum YKL-40 levels were significantly elevated in patients with carotid atherosclerosis, with particularly high levels in those with symptomatic disease; (2) patients with recent ischemic symptoms (within 2 months) had higher YKL-40 mRNA levels in carotid plaque than other patients; (3) in vitro, the beta-adrenergic receptor agonist isoproterenol, toll-like receptor (TLR) 2 and TLR4 agonists, and in particular releasate from activated platelets significantly increased the expression of YKL-40 in THP-1 monocytes and (4) in vitro, YKL-40 increased matrix metalloproteinase-9 expression and activity in THP-1 monocytes, involving activation of p38 mitogen-activated protein kinase. Conclusions: Our findings suggest that YKL-40 might be a marker of plaque instability, potentially reflecting macrophage activation and matrix degradation within the atherosclerotic lesion. (C) 2010 Elsevier Ireland Ltd. All rights reserved
Original languageEnglish
JournalAtherosclerosis
Volume211
Issue number2
Pages (from-to)589-595
Number of pages7
ISSN0021-9150
DOIs
Publication statusPublished - 2010

ID: 34097218